1,3,5-trimethyl-1H-pyrazolo[3,4-b]pyridine | 51431-36-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡唑并吡啶类
• 英文名称: 1,3,5-trimethyl-1H-pyrazolo[3,4-b]pyridine
• 英文别名: 1,3,5-Trimethylpyrazolo[3,4-b]pyridine
• CAS: 51431-36-8
• 化学式: C₉H₁₁N₃
• 分子量: 161.206
• InChiKey: YYNYNQITPQSDAE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  12
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  30.7
• 氢给体数：
  0
• 氢受体数：
  2

文献信息

• FUSED RING HETEROCYCLE KINASE MODULATORS
  申请人：Chen Chixu

  公开号：US20080261921A1

  公开（公告）日：2008-10-23

  The present invention provides fused ring heterocycles as kinase modulators, pharmaceutical compositions containing these modulators, and methods of using these modulators to treat diseases mediated by kinase activity.

  本发明提供了融合环杂环化合物作为激酶调节剂，含有这些调节剂的药物组合物，以及使用这些调节剂治疗由激酶活性介导的疾病的方法。
• COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY
  申请人：Li Hui

  公开号：US20100190770A1

  公开（公告）日：2010-07-29

  Disclosed are compounds of formula I, compositions containing them, and methods of use for the compounds and compositions in the treatment of conditions in which modulation of the JAK pathway or inhibition of JAK kinases, particularly JAK 2 and JAK3, are therapeutically useful.

  公开了化合物I的结构，含有这些化合物的组合物，以及在治疗需要调节JAK途径或抑制JAK激酶，特别是JAK 2和JAK3的情况下使用这些化合物和组合物的方法。
• Fused Ring Heterocycle Kinase Modulators
  申请人：Arnold William D.

  公开号：US20100036118A1

  公开（公告）日：2010-02-11

  The present invention provides novel fused ring heterocycle kinase modulators and methods of using the novel fused ring heterocycle kinase modulators to treat diseases mediated by kinase activity.

  本发明提供了新型融合环杂环激酶调节剂和使用这些新型融合环杂环激酶调节剂治疗由激酶活性介导的疾病的方法。
• Macrolides Useful Against Inflammatory and Allergic Diseases
  申请人：Kellenberger Johannes Laurenz

  公开号：US20100120706A1

  公开（公告）日：2010-05-13

  Macrolide compounds of formula I: with PDF4 inhibiting activity are described, wherein R1 is a residue —Y—X-Q; Y is S, SO or SO 2 ; X is a bond or a linear group consisting of hydrogen atoms and with up to 9 atoms selected from C, N, O and/or S, of which up to 2 atoms can be N and one atom can be O or S, one carbon atom can appear as a CO group and the sulphur atom can appear as an SO2 group and two adjacent C atoms can be present as —CH═CH— or —C≡C— and which group X is unsubstituted or is substituted with —COO—W or —CONH—W; Q is a residue —V-A1-L-A2-W or, if X does not represent a bond, may also be —NR6R7; V is a divalent aromatic or heterocyclic group; W is aryl or heterocyclyl; or in a group —V-A1-L-A2-W, wherein at least one of the groups A1; L or A2 is present, can also be a monovalent substituted or unsubstituted, saturated or unsaturated linear group with up to 5 atoms consisting of C, N, O and/or S of which one carbon can appear as a CO group one sulphur atom can appear as an SO2 group, A1, A2 are independently of each other either absent or a C 1 -C 4 alkylene group; L is —O—, —S—, —SO2-, —NH—, —CO—, —(CO)O—, —O(OC)—, —(CO)NH—, —NH(CO)—, —(SO 2 )NH—, —HN(SO 2 )—, —HN(CO)NH—, —O(CO)NH—, —NH(CO)O—, or can also be absent if A1 and/or A2 are present; R2 is hydrogen and R3 is and OR4 or R2, R3 taken together form a C═O group; R4 is hydrogen or an saturated or unsaturated aliphatic group with 1 to 6 carbon atoms; R6, R7 are independently selected from aryl; aralkyl; heterocyclyl and heterocyclylalkyl; and one of R6 and R7 can also be a group -L-W; and * indicates a chiral centre which is in the (R) or (S) form.

  本文描述了具有PDF4抑制活性的公式I的大环内酯化合物，其中R1是一个残基-Y-X-Q; Y是S，SO或SO2; X是一个键或由氢原子组成的线性基团，其中可选的原子有C，N，O和/或S，其中最多有2个原子可以是N，一个原子可以是O或S，一个碳原子可以出现为CO基团，硫原子可以出现为SO2基团，两个相邻的C原子可以出现为-CH═CH-或-C≡C-，并且该基团X未被取代或被取代为-COO-W或CONH-W; Q是一个残基-V-A1-L-A2-W或，如果X不表示键，则也可以是-NR6R7; V是一个双价芳香或杂环基团; W是芳基或杂环基团; 或在一个组-V-A1-L-A2-W中，其中至少有一个A1；L或A2也可能是一个单价取代或未取代的饱和或不饱和线性基团，其中最多有5个原子，包括C，N，O和/或S，其中一个碳可以出现为CO基团，一个硫原子可以出现为SO2基团，A1，A2彼此独立地不存在或是C1-C4烷基基团; L是-O-，-S-，-SO2-，-NH-，-CO-，-(CO)O-，-O(OC)-，-(CO)NH-，-NH(CO)-，-(SO2)NH-，-HN(SO2)-，-HN(CO)NH-，-O(CO)NH-，-NH(CO)O-，或者如果A1和/或A2存在，则L也可以不存在; R2是氢，R3是OR4或R2，R3共同形成一个C═O基团; R4是氢或含有1到6个碳原子的饱和或不饱和脂肪基团; R6，R7独立地选自芳基；芳基烷基；杂环基和杂环基烷基；其中R6和R7中的一个也可以是一个-L-W基团; *表示一个手性中心，它是(R)或(S)形式。
• COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR
  申请人：Plexxikon Inc.

  公开号：US20140213554A1

  公开（公告）日：2014-07-31

  Compounds active on c-kit protein kinases or mutant c-kit protein kinases having any mutations are described, as well as methods of making and using such compounds to treat diseases and conditions associated with aberrant activity of the c-kit protein kinases and/or mutant c-kit protein kinases.

  本文介绍了对c-kit蛋白激酶或带有任何突变的突变c-kit蛋白激酶活性的化合物，以及制备和使用这些化合物治疗与c-kit蛋白激酶和/或突变c-kit蛋白激酶的异常活性相关的疾病和病状的方法。